Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

121 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the project is to improve adolescent behavioral counseling services in healthcare settings with a new Internet/Intranet-based Motivational Enhancement Therapy (iMET) intervention that targets the use of tobacco, alcohol, and other drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Smoking Cessation for Young Adults Who Binge Drink - 1

NCT00218452

Adherence Tobacco Use Cessation Alcohol & Drug Use +1 more

COMPLETED EARLY_PHASE1

Working Inside for Smoking Elimination

NCT01122589

Cigarette Smoking Tobacco Smoking

UNKNOWN NA

Contingency Management for Smoking Abstinence With Adolescent Smokers

NCT01056588

Cigarette Smoking

COMPLETED NA

Implementing Tobacco Control in Dental Practice

NCT00297700

Smoking

UNKNOWN PHASE3

Exploring a Cessation Intervention for Smokers

NCT01728038

Asthma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We have previously developed and tested in a treatment population a promising MET program for alcohol and drug use. We will broaden the MET intervention to also target tobacco use and convert the new materials into a self-administered format.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Use; Tobacco, Harmful Alcohol Abuse Drug Abuse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment as usual

Participants will receive treatment as usual from their provider.

Group Type NO_INTERVENTION

No interventions assigned to this group

iMET

Participants will receive the iMET intervention.

Group Type EXPERIMENTAL

iMET

Intervention Type BEHAVIORAL

Participants will receive the iMET intervention

iMET/TE

Participants will receive the iMET intervention and Technological Extenders (TEs).

Group Type EXPERIMENTAL

iMET/TE

Intervention Type BEHAVIORAL

Participants will receive the iMET intervention and also receive TEs (Technological Extenders)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iMET

Participants will receive the iMET intervention

Intervention Type BEHAVIORAL

iMET/TE

Participants will receive the iMET intervention and also receive TEs (Technological Extenders)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 12-21 years old
* Coming for routine care

Exclusion Criteria

* Medically or emotionally unstable day of visit
* Already receiving behavioral health services
* Cannot read/understand English
* Will not be available for post-tests

Minimum Eligible Age

12 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

John R Knight, MD

Associate Professor of Pediatrics, Harvard Medical School; Senior Associate in Medicine; Associate in Psychiatry, Director, Center for Adolescent Substance Abuse Research, Boston Children's Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR